The larger dataset continues to demonstrate that this combination offers superior efficacy and durability compared to what has been reported for standard of care and other investigational therapies in third line metastatic MSS CRC. The data were presented in the opening late-breaking oral session at the
This data highlight the deep and durable responses achieved with botensilimab and balstilimab in advanced MSS CRC, underscoring remarkable benefit for these patients who have failed standard of care or other investigative therapies. With over 300 patients enrolled to date, botensilimab alone and in combination with balstilimab have demonstrated durable clinical responses across nine cold and treatment-resistant cancers,' said
MSS CRC accounts for over 95% of metastatic CRC cases and is characterized by tremendous unmet need, as available treatments have reported single digit responses rates,' said
Study Design and Highlights:
A total of 70 evaluable patients with refractory metastatic MSS CRC received either 1 or 2 mg/kg botensilimab every 6 weeks and 3 mg/kg balstilimab every 2 weeks.
Patient Demographics: Heavily pre-treated, with a median of 4 prior lines of therapy 31% had received prior immunotherapy Objective responses: 23% overall response rate Other PD-(L)1 + CTLA-4 combinations in comparable patient populations have reported 1-5% response rates1,2 69% of objective responses were ongoing at data cut-off 76% disease control rate (complete response + partial response + stable disease)
Survival: 12-month overall survival of 63% Reported 12-month overall survival for standard of care is 25% Median overall survival has not been reached Tolerability: Manageable gastrointestinal toxicity with a differentiated overall safety profile
Presentation Details: Abstract Title: Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) (NCT03860272)
Abstract Number: LBA8
Presenting Author:
Following the symposium, an archived version of the presentation will be available in the Publications section of the
About
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans and any other statements containing the words 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'will' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the
Contact:
Tel: (917) 362-1370
(C) 2023 Electronic News Publishing, source